PRT2527

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

Arms / Cohorts

Experimental:PRT2527 Monotherapy in Lymphoid Malignancies

Accepting patients

Experimental:PRT2527/Zanubrutinib Combination in Lymphoid Malignancies

Accepting patients

Experimental:PRT2527 Monotherapy in Myeloid Malignancies

Accepting patients

Experimental:PRT2527/Venetoclax Combination in Myeloid Malignancies

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.